Companies › Lupin
1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Neurology; next expected readout Jan 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mexiletine Sodium channel alpha subunit blocker | Ion channels | Phase 3 | Myotonia; Myotonic Dystrophy; Spinal and Bulbar Muscular Atrophy | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07097701 | Mexiletine | Phase 3 | Myotonia | Neurology | Jan 2027 |
| NCT06523400 | Mexiletine | Phase 3 | Myotonic Dystrophy | Neurology | Jun 2027 |
| NCT06862596 | Mexiletine | Phase 2 | Spinal and Bulbar Muscular Atrophy | Neurology | Dec 2027 |
Stoke Therapeutics Sandoz Merz Pharmaceuticals Neurona Therapeutics Actio Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.